Xilio Therapeutics (XLO)
(Delayed Data from NSDQ)
$1.08 USD
+0.15 (16.12%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.05 -0.03 (-2.78%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Income Statements
Fiscal Year end for Xilio Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 79 | 89 | 75 | 55 | 0 |
Income After Depreciation & Amortization | -79 | -89 | -75 | -55 | 0 |
Non-Operating Income | 3 | 1 | -1 | -1 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -76 | -88 | -76 | -55 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -76 | -88 | -76 | -55 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -76 | -88 | -76 | -55 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -77 | -87 | -74 | -53 | 0 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 2 | 1 | NA |
Income After Depreciation & Amortization | -79 | -89 | -75 | -55 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 27.50 | 27.39 | 5.61 | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.78 | -3.22 | -13.52 | NA | NA |
Diluted Net EPS (GAAP) | -2.78 | -3.22 | -13.52 | NA | NA |
Fiscal Year end for Xilio Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 17.49 | 18.13 | 17.36 | 20.12 | 23.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | -17.49 | -18.13 | -17.36 | -20.12 | -23.53 |
Non-Operating Income | 0.28 | 0.48 | 0.61 | 0.76 | 0.88 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -17.20 | -17.66 | -16.75 | -19.36 | -22.65 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -17.20 | -17.66 | -16.75 | -19.36 | -22.65 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -17.20 | -17.66 | -16.75 | -19.36 | -22.65 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 27.91 | 27.56 | 27.52 | 27.47 | 27.43 |
Diluted EPS Before Non-Recurring Items | -0.59 | -0.64 | -0.61 | -0.70 | -0.83 |
Diluted Net EPS (GAAP) | -0.62 | -0.64 | -0.61 | -0.70 | -0.83 |